Abstract:
Purpose: This study evaluated the impact of a newly established clinic for the diagnosis of pediatric epilepsy in a resource-limited center (Ifakara, Tanzania).
Methods: Patients aged 0–18 years referred to the Pediatric Epilepsy Unit of Saint Francis Referral
Hospital were recruited. Demographic and clinical data were collected through Kobo Toolbox and analyzed through a descriptive analysis..
Results: 143 patients were evaluated, and for 48 of them an EEG was recorded (abnormalities were
detected in 80.85% of the cases). The diagnosis of epilepsy was confirmed in 87 patients. Focal epilepsy
was diagnosed in 57 patients, generalized epilepsy in 24 patients, and forms of unknown onset in 6
patients. Epilepsy was excluded for 9 children. Etiologies included hypoxic-ischemic encephalopathy
(39%), central nervous system infections (3.4%), and genetic diseases (3.4%). A specific epilepsy syndrome
was diagnosed in 16 patients. 74 patients were under treatment; the most used antiseizure medication
(ASM) was phenobarbital (43.36%), followed by carbamazepine (16.08%), sodium valproate (11.19%),
phenytoin (2.8%), and lamotrigine (0.7%). Therapeutic changes were proposed to 95 patients, more frequently consisting of withdrawing phenobarbital (39.16%), switching to sodium valproate (27.97%),
switching to or adjusting carbamazepine dosage (27.27%), and starting prednisone (2.8%). 76% of the
patients with confirmed epilepsy achieved complete seizure freedom at the fourth follow-up consultation.
Conclusions: Our data depicted the epilepsy spectrum and highlighted the prognostic implications of improving the availability of ASMs such as sodium valproate and second- and third-generation ones in resource-limited countries.
